Adaptimmune Therapeutics Plc (ADAPY)
0.046
0.00 (0.00%)
USD |
OTCM |
Dec 04, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 12.19M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -93.43% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 0.1809 |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -0.686 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 99.62% |
Profile
| Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel, and ADP-A2M4CD8. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom. |
| URL | http://www.adaptimmune.com |
| Investor Relations URL | https://www.adaptimmune.com/investors-and-media |
| HQ State/Province | Oxfordshire |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Dec. 05, 2025 (est.) |
| Last Earnings Release | Dec. 05, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel, and ADP-A2M4CD8. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom. |
| URL | http://www.adaptimmune.com |
| Investor Relations URL | https://www.adaptimmune.com/investors-and-media |
| HQ State/Province | Oxfordshire |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Dec. 05, 2025 (est.) |
| Last Earnings Release | Dec. 05, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |